CLIP3 and glioblastoma: Based on this background, we hypothesized that a CLIP3-activating drug which has already been approved by the FDA successfully targets self-renewal and metabolic pathway mechanism of GBM, distinct from the current treatment approaches which solely target cell proliferation.